CLC Bio said this week that it saw a 30 percent rise in software sales in 2012, along with similar growth in its employee headcount.
The privately held firm, based in Aarhus, Denmark, said that it added more than 500 new customers last year.
The company now has more than 2,000 customers and more than 100 employees, CLC Bio CEO Thomas Knudsen said in statement. He said that the company is profitable and has a positive cashflow, which it will use to support further growth in the years to come.
The company did not provide additional details its revenues, though Lasse Gorlitz, vice president of communications, told BioInform that sales in Japan doubled during the year.
CLC Bio sells 98 percent of its software internationally, with about 50 percent of the sales going to customers in the US.
The company's activity for the past year includes its acquisition of Molegro, a developer of molecular modeling software, for an undisclosed sum (BI 9/7/2012).
Commenting on the purchase, Knudsen described the move as a "positive" one for CLC Bio and said that his firm would offer more drug discovery software to the market in future.
Also in 2012, the Danish firm joined two European Union funded projects: Pathseek, which is focused on using next-generation sequencing to detect pathogens and drug-resistant mutations; and STATegra, which aims to create statistical methods for analyzing a wide range of omics datasets.
CLC Bio said that these two projects contributed $2.9 million to its total income for 2012.
The company was also tapped to provide bioinformatics capabilities for a third EU-funded project that is studying the mechanisms involved in stem cell differentiation (BI 9/17/2012).